Key result
Statin therapy is significantly underutilized as ~44% of untreated Korean cancer survivors meet eligibility guidelines.
Why the study?
Cardiovascular disease is a leading cause of non-cancer mortality in cancer survivors, but the status of dyslipidemia management with reference to 2018 guidelines was unclear.
What is the prevalence of statin undertreatment among Korean cancer survivors eligible for dyslipidemia management?
Cross-Sectional (n=1,460)
Yes
What is the prevalence of statin undertreatment among Korean cancer survivors eligible for dyslipidemia management?
Nearly half of Korean cancer survivors eligible for statin therapy remain untreated, highlighting a significant gap in atherosclerotic cardiovascular disease prevention in this population.
High undertreatment of eligible cancer survivors signals need for improved screening; leaves open whether guideline-directed statins alter outcomes in this group.
AIMS: Due to improving cancer treatment results, non-cancer mortality is an important issue for cancer survivors. Cardiovascular diseases are the leading causes of death in Korea and globally. In addition to lowering the risk of cardiovascular disease, the use of statins has led to an overall reduction in cancer mortality in recent observational studies. We investigated the status of current dyslipidemia management in cancer survivors with reference to 2018 guidelines. METHODS: The study is a cross-sectional analysis of 1460 cancer survivors aged from 40 to 75 years who participated in the Korean National Health and Nutrition Examination Survey from 2007 to 2016. Dyslipidemia management status among cancer survivors was assessed according to 2018 American College of Cardiology/American Heart Association guidelines and Korean Coronary Heart Disease Risk Score guidelines. RESULTS: The rate of treatment for dyslipidemia was 8.5% for males, 13.8% for females, and 11.9% overall. Among cancer survivors who were not receiving treatment for dyslipidemia, 59.6% of males, 34.2% of females and 43.9% of total cancer survivors would have been eligible for statin therapy under the 2018 American College of Cardiology/American Heart Association guidelines and Korean Coronary Heart Disease Risk Score guidelines. The rate of undertreatment of dyslipidemia increased with age and length of time since cancer diagnosis. CONCLUSION: Nearly 50% of cancer survivors remain untreated although they are eligible for statin therapy. This emphasizes the need for more attention to prevent atherosclerotic cardiovascular disease among cancer survivors.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2020) conducted a cross-sectional in cancer survivors (n=1,460). Dyslipidemia management and statin therapy eligibility was evaluated on Eligibility for statin therapy among untreated cancer survivors. Among Korean cancer survivors not receiving treatment for dyslipidemia, 43.9% were eligible for statin therapy under 2018 guidelines, indicating significant undertreatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: